Early Treatment of COVID-19 Disease: A Missed Opportunity
Open Access
- 13 October 2020
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Infectious Diseases and Therapy
- Vol. 9 (4), 715-720
- https://doi.org/10.1007/s40121-020-00349-8
Abstract
Antivirals have demonstrated efficacy in treating other infectious diseases in early stages of disease, reducing morbidity, mortality, and the likelihood of onward transmission. At the time of writing, more than 1900 clinical trials are registered globally to assess the efficacy and safety of candidate therapeutics for COVID-19. The majority of these trials are designed to evaluate the comparative efficacy and safety of candidate therapeutics for the treatment of COVID-19 to prevent death among populations of hospitalized patients with advanced disease. Yet, emerging epidemiological evidence now indicates that the majority of those infected with the SARS-CoV-2, while still infectious, experience minimal or mild disease symptomology. Like HIV and hepatitis C that pioneered treatment as prevention, there is a missed opportunity for trials of early pharmaceutical intervention for COVID-19 disease evaluating not only reductions in morbidity and mortality but also transmissibility. We discuss this clinical research gap within an historical context of viral treatment as prevention for HIV and hepatitis C, and comment on the challenges and opportunities for clinical research of candidate therapeutics for early COVID-19 disease.Keywords
Funding Information
- Bill and Melinda Gates Foundation
This publication has 19 references indexed in Scilit:
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19New England Journal of Medicine, 2020
- Coronavirus: Update Related to the Current Outbreak of COVID-19Infectious Diseases and Therapy, 2020
- Mould Infections of Traumatic Wounds: A Brief Narrative ReviewInfectious Diseases and Therapy, 2020
- Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemicsBritish Journal of Clinical Pharmacology, 2017
- Age-targeted HIV treatment and primary prevention as a 'ring fence' to efficiently interrupt the age patterns of transmission in generalized epidemic settings in South Africa.International Health, 2016
- Initiation of Antiretroviral Therapy in Early Asymptomatic HIV InfectionNew England Journal of Medicine, 2015
- Treatment as prevention and cure towards global eradication of hepatitis C virusTrends in Microbiology, 2013
- HIV treatment as prevention: The key to an AIDS-free generationJournal of Food and Drug Analysis, 2013
- An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adultsAIDS, 2006
- The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemicThe Lancet, 2006